Scandinavian ChemoTech updates its focus in Human Care as new management make progress in India
In the wake of the pandemic, Scandinavian ChemoTech strengthened its management to improve on the ability to faster reach success on its main market, being large enough to reach a major clinical and financial breakthrough.
After ChemoTech extended its management team with three new members, a stronger focus on India was initiated. With our new Medical Director, Global Commercial Director, and Head of R&D onboard, our primary commercial focus is to establish significant success in both sales and clinical development projects. ChemoTech appointed a new management for the Indian and Southeast Asian markets to ensure that we reach the long-term targets of being part of Standard of Care for head and neck- and breast cancer.
After six intensive months, the team reports back that the interest in TSE is very strong and continues to grow.
“Our target is to have 15 new commercial installations on sales, rent or leasing programs at the end of 2023 and we will continue the process to get IQwave listed on the federal procurement list for medical devices in India,” says Deepak Sharma, Head of Commercial Operations, as a part time consultant, at Scandinavian ChemoTech.
“I am very happy that our progress the last years have taken us to where we are today in India with a CoE at AIIMS Jodhpur and a commercial and clinical management of highest calibre. The number of leads that our Indian organisation receives on weekly basis for clinical and commercial partnerships are very promising and a result of hard work”, says Mohan Frick CEO and cofounder of Scandinavian ChemoTech.
This information is such information that Scandinavian ChemoTech AB is obliged to make public according to the EU's market abuse regulation. The information was provided, through the agency of the contact person, for publication on 2023-04-20 at 11.15 CET.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Certified Adviser: Redeye AB, Tel: +46 (0)8 - 121 576 90
E-mail: certifiedadviser@redeye.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.